Odonate Therapeutics, Inc.
ODTC · OTC
12/31/2022 | 9/30/2022 | 12/31/2021 | 9/30/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $3 |
| G&A Expenses | $0 | $0 | $0 | $1 |
| SG&A Expenses | $0 | $2 | $3 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $0 | $2 | $3 | $4 |
| Operating Income | -$0 | -$2 | -$3 | $12 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $6 | $7 | $5 | -$26 |
| Pre-Tax Income | $6 | $5 | $1 | -$14 |
| Tax Expense | $1 | -$34 | $0 | $0 |
| Net Income | $5 | $39 | $1 | -$14 |
| % Margin | – | – | – | – |
| EPS | 4,330.567 | 36,411.025 | 1,287.871 | -9,841.349 |
| % Growth | -88.1% | 2,727.2% | 113.1% | – |
| EPS Diluted | 4,330.567 | 36,349.698 | 1,287.871 | -9,841.349 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $6 | $5 | -$3 | -$14 |
| % Margin | – | – | – | – |